Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $53.43M
• Dividend Yield: N/A
• Average Volume (3M): 22.02K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.78
• Revenue Growth: 34.04%
• EPS Growth: 55.34%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 9,967,381
• 10 Day Avg. Volume: 33,075
• 30 Day Avg. Volume: 22,016
• PEG Ratio: -0.58
• Price to Book (P/B): 31.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.76
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 110.88
• Enterprise Value/Gross Profit: -1.02K
• Enterprise Value/Ebitda: -2.30
• 1Y Price Target: $13.00
• Price Target Upside: 142.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 47 Neutral
• Price Target: $5.00 ▼(-6.72%Downside)

The overall stock score for Serina Therapeutics reflects significant financial challenges, including substantial losses and negative cash flow, which are the most impactful factors. The bearish technical indicators and negative valuation metrics further weigh on the stock's prospects. However, the recent breakthrough in LNP technology provides a positive aspect, potentially improving the company's future strategic position.

Positive Factors

Drug Innovation

SER-252 could represent a best-in-class solution for deployment of apomorphine in advanced PD patients.

Market Potential

POZ-Apomorphine targets substantial Advanced Parkinson's Disease market with potential for key clinical/commercial advantages.

Regulatory Approval

The discussion highlighted the company's clear vision of SER-252's path for regulatory approval, with a potential for 505(b)2 and associated reductions in timelines and costs, and their confidence they can reach the clinical benchmarks required to be approved.

Negative Factors

Current Treatment Challenges

Current formulations of apomorphine (APOKIN and ONAPGO, both marketed by Supernus Pharmaceuticals) have severe adverse events, which can hinder treatment compliance.

Market Competition

63% of patients treated with competing product ONAPGO experience infusion site reactions, highlighting potential challenges in the market.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics makes money by developing and licensing its proprietary POZ technology to pharmaceutical companies seeking to improve the delivery and efficacy of their existing drugs. The company generates revenue through licensing agreements, research and development collaborations, and royalty payments from its partners. These partnerships enable Serina Therapeutics to leverage its technology in combination with the drug development expertise of its partners, thereby expanding its reach and market potential. Additionally, the company may receive milestone payments based on the successful development and commercialization of products utilizing its technology, contributing to its overall revenue streams.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	-138.00K	-29.00K	355.00K	2.89M	-1.23M
EBITDA	-10.49M	5.92M	-2.60M	-7.35M	-8.74M
Net Income	-11.14M	5.27M	-2.68M	-8.68M	-10.87M
Balance Sheet
Total Assets	6.72M	11.96M	858.04K	1.84M	3.92M
Cash, Cash Equivalents and Short-Term Investments	3.67M	345.00K	532.23K	1.31M	527.00K
Total Debt	268.00K	4.37M	1.81M	398.17K	6.30M
Total Liabilities	6.22M	6.61M	38.64M	36.95M	9.32M
Stockholders Equity	641.00K	5.47M	-37.78M	-35.11M	-5.12M
Cash Flow
Free Cash Flow	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 5.36 is below the 20-day moving average (MA) of 5.69, below the 50-day MA of 5.76, and below the 200-day MA of 5.46, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 44.32 is Neutral, neither overbought nor oversold. The STOCH value of 28.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥347.74B	11.06	-2.99%	3.68%	11.77%	-10.16%
VRCA	54 Neutral	$75.50M	―	-1546.58%	―	-19.45%	31.22%
KRON	51 Neutral	$53.65M	―	-59.49%	―	21.15%	46.44%
PDSB	50 Neutral	$52.57M	―	-119.22%	―	―	25.51%
SER	47 Neutral	$53.43M	―	45.59%	―	34.04%	55.34%
GANX	46 Neutral	$54.80M	―	-290.21%	―	-100.00%	44.28%
STRO	39 Underperform	$64.19M	―	-679.15%	―	-56.88%	-57.57%

Serina Therapeutics Corporate Events

Serina Therapeutics Announces 2025 Annual Meeting Date

Serina Therapeutics announced that its 2025 annual meeting of stockholders will be held on November 7, 2025. The change in the meeting date from the previous year affects the deadline for stockholder proposals, which is set for August 15, 2025. This adjustment provides stakeholders with a new timeline for submitting proposals and nominations, ensuring compliance with regulatory requirements and the company’s bylaws.

The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Appoints Dr. Stephen Brannan to Board

On May 22, 2025, Serina Therapeutics announced the appointment of Dr. Stephen Brannan to its Board of Directors, bringing extensive expertise in neuroscience and neuropsychiatry drug development. Dr. Brannan’s experience, notably his role in the successful development of KarXT at Karuna Therapeutics, aligns with Serina’s focus on long-acting CNS treatments. Concurrently, Remy Gross departed from the Board, transitioning to a consulting role, having contributed significantly to Serina’s growth.

The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.